Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Sales Growth Strategy Is DTC Ads, “Cleverly Crafted” Phase IVs

Executive Summary

Novartis is considering expanded use of direct-to-consumer ads based on the positive results of DTC campaigns for Elidel, Zelnorm and Lamisil

You may also be interested in...



Novartis Plans Chronic Constipation Disease Ads Following Zelnorm Approval

Novartis plans to begin a patient-directed disease awareness campaign on chronic constipation in 2005

Novartis Plans Chronic Constipation Disease Ads Following Zelnorm Approval

Novartis plans to begin a patient-directed disease awareness campaign on chronic constipation in 2005

Protopic, Elidel Safety Labeling May Be Reviewed, FDA Tells Pediatric Cmte.

FDA plans to discuss the pediatric safety profile of topical immunosuppressants with Novartis and Fujisawa after an advisory committee recommended stronger warnings about the potential carcinogenicity of Elidel and Protopic

Related Content

UsernamePublicRestriction

Register

PS042708

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel